Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/boditech-med-inc">Boditech Med</a> Inc. (206640 KS) is a leading South Korea-based in vitro diagnostics (IVD) company specializing in Point-of-Care Testing (POCT) analyzers (ichroma™ and AFIAS platforms) and consumable diagnostic reagent cartridges across more than 120 global markets.</li>
  <li>Following post-pandemic normalization, the company has delivered strong organic revenue expansion, reaching KRW 162.1bn in 2025 (+17.3% YoY) with sustained gross profit margins above 56% and EBITDA margins in the 23-26% range, powered by non-COVID test menus across cardiovascular, latent tuberculosis (IGRA-TB), therapeutic drug monitoring (TDM), and diabetes.</li>
  <li>Trading at attractive valuation multiples relative to global IVD peers (~7.5-8.5x trailing P/E and ~1.1x P/B), <a href="https://smartkarma.com/entities/boditech-med-inc">Boditech Med</a> combines robust balance sheet resilience (net cash position), consistent dividend distributions (1.6% yield), and multiple regulatory commercial catalysts in North America and Europe.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Boditech Med Inc. (206640 KS) is a leading South Korea-based in vitro diagnostics (IVD) company specializing in Point-of-Care Testing (POCT) analyzers (ichroma™ and AFIAS platforms) and consumable diagnostic reagent cartridges across more than 120 global markets.
  Following post-pandemic normalization, the company has delivered strong organic revenue expansion, reaching KRW 162.1bn in 2025 (+17.3% YoY) with sustained gross profit margins above 56% and EBITDA margins in the 23-26% range, powered by non-COVID test menus across cardiovascular, latent tuberculosis (IGRA-TB), therapeutic drug monitoring (TDM), and diabetes.
  Trading at attractive valuation multiples relative to global IVD peers (~7.5-8.5x trailing P/E and ~1.1x P/B), Boditech Med combines robust balance sheet resilience (net cash position), consistent dividend distributions (1.6% yield), and multiple regulatory commercial catalysts in North America and Europe.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Boditech Med (206640 KS) - Sep 2026

South Korea

Boditech Med Inc. researches and develops "In Vitro" diagnostics (IVD) instruments and reagents.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Boditech Med (206640 KS) - Sep 2026

Boditech Med Inc. (206640 KS) is a leading South Korea-based in vitro diagnostics (IVD) company specializing in Point-of-Care Testing (POCT)...

αSK Primers